ARK Investment Management LLC Has $534.36 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,536,104 shares of the company’s stock after buying an additional 1,372,986 shares during the period. CRISPR Therapeutics accounts for approximately 3.2% of ARK Investment Management LLC’s investment portfolio, making the stock its 9th biggest position. ARK Investment Management LLC owned approximately 10.75% of CRISPR Therapeutics worth $534,360,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRSP. Price T Rowe Associates Inc. MD lifted its stake in CRISPR Therapeutics by 158.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock valued at $183,194,000 after acquiring an additional 1,848,437 shares during the last quarter. State Street Corp lifted its stake in CRISPR Therapeutics by 228.8% in the second quarter. State Street Corp now owns 1,569,860 shares of the company’s stock valued at $95,400,000 after acquiring an additional 1,092,384 shares during the last quarter. BlackRock Inc. lifted its stake in CRISPR Therapeutics by 79.2% in the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock valued at $143,038,000 after acquiring an additional 1,007,246 shares during the last quarter. Vanguard Group Inc. lifted its stake in CRISPR Therapeutics by 261.4% in the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock valued at $76,410,000 after acquiring an additional 880,463 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its stake in CRISPR Therapeutics by 33.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,993,577 shares of the company’s stock valued at $121,689,000 after acquiring an additional 752,132 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Down 1.1 %

CRSP stock opened at $70.16 on Thursday. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. The firm has a market cap of $5.63 billion, a P/E ratio of -35.80 and a beta of 1.79. The company’s 50-day moving average price is $73.75 and its two-hundred day moving average price is $61.71.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 8.09%. The company had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same period last year, the company posted ($1.41) EPS. The firm’s quarterly revenue was up 3253.3% compared to the same quarter last year. Equities analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total transaction of $1,449,600.00. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $15,084,682.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total transaction of $1,449,600.00. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $15,084,682.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now owns 6,476 shares in the company, valued at $470,740.44. The disclosure for this sale can be found here. Insiders have sold a total of 134,410 shares of company stock worth $9,234,677 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. TD Cowen cut shares of CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research note on Monday, December 11th. Truist Financial reissued a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, December 8th. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Morgan Stanley increased their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Finally, Royal Bank of Canada increased their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $74.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.